Shisi Pharmaceutical Group (02005): Fenofibrate Choline Sustained Release Capsule (135mg) obtained drug production registration approval

Zhitong Finance App News, Shisi Pharmaceutical Group (02005) issued an announcement. The Group has obtained approval from the China National Drug Administration for the production of phenobibrate choline sustained-release capsules (135mg), which is a Class 4 chemical drug, and is deemed to have passed the consistency evaluation.

Fenofibrate choline sustained-release capsules are mainly used to reduce triglyceride levels in patients with severe hypertriglyceridemia and to treat patients with primary hypercholesterolemia or mixed dyslipidemia on the basis of a controlled diet for adults. Compared with traditional fenofibrate, fenofibrate choline has a direct effect, has a lower liver and kidney burden, is not restricted by eating, and can be safely combined with statins. It is a high-end triglyceride-lowering replacement product that is just needed clinically.